
Company valuation, historical trends, and peer comparisons.
According to MoonLake Immunotherapeutics’s latest financial reports and current stock price. The company's current Enterprise Value is 622.63M. This represents a change of -15.97% compared to the average of 740.95M of the last 4 quarters.
The mean historical Enterprise Value of MoonLake Immunotherapeutics over the last ten years is 1.19B. The current 622.63M Enterprise Value has changed -47.71% with respect to the historical average. Over the past ten years (40 quarters), MLTX's Enterprise Value was at its highest in in the December 2024 quarter at 3.24B. The Enterprise Value was at its lowest in in the June 2022 quarter at 92.10M.
Average
1.19B
Median
481.49M
Minimum
167.05M
Maximum
3.23B
Discovering the peaks and valleys of MoonLake Immunotherapeutics Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 836.20%
Maximum Annual Enterprise Value = 3.23B
Minimum Annual Increase = -81.69%
Minimum Annual Enterprise Value = 167.05M
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 590.83M | -81.69% |
| 2024 | 3.23B | 28.10% |
| 2023 | 2.52B | 836.20% |
| 2022 | 269.07M | -27.70% |
| 2021 | 372.16M | 122.77% |
The current Enterprise Value of MoonLake Immunotherapeutics (MLTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
2.11B
5-year avg
1.40B
10-year avg
1.19B
MoonLake Immunotherapeutics’s Enterprise Value is less than AnaptysBio, Inc. (1.57B), greater than Aclaris Therapeutics, Inc. (560.80M), less than Attovia Therapeutics, Inc. (678.64M), less than Nurix Therapeutics, Inc. (2.20B), greater than Connect Biopharma Holdings Limited (23.88M), less than Dianthus Therapeutics, Inc. (4.53B), less than Oruka Therapeutics, Inc. (6.11B), greater than Zura Bio Limited (198.61M), less than Alumis Inc. (827.64M), greater than Equillium, Inc. (31.49M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 1.57B | $1.43B | |
| 560.80M | $579.96M | |
| 678.64M | $707.14M | |
| 2.20B | $2.85B | |
| 23.88M | $50.30M | |
| 4.53B | $4.64B | |
| 6.11B | $6.38B | |
| 198.61M | $386.26M | |
| 827.64M | $854.92M | |
| 31.49M | $88.07M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MoonLake Immunotherapeutics using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MoonLake Immunotherapeutics or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is MoonLake Immunotherapeutics's Enterprise Value?
What is the highest Enterprise Value for MoonLake Immunotherapeutics (MLTX)?
What is the 3-year average Enterprise Value for MoonLake Immunotherapeutics (MLTX)?
What is the 5-year average Enterprise Value for MoonLake Immunotherapeutics (MLTX)?
How does the current Enterprise Value for MoonLake Immunotherapeutics (MLTX) compare to its historical average?